



37 ethers, whenever the existence of these isomers, esters, ethers  
38 and salts is possible within the specific chemical designation:

39 (1) Acetyl-alpha-methylfentanyl  
40 (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);

41 (2) Acetylmethadol;

42 ( \* \* \*3) Acetyl fentanyl  
43 (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);

44 (4) Acryl fentanyl  
45 (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide), also known as  
46 acryloylfentanyl;

47 ( \* \* \*5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)  
48 cyclohexylmethyl]benzamide);

49 \* \* \*

50 ( \* \* \*6) Allylprodine;

51 ( \* \* \*7) Alphacetylmethadol, except  
52 levo-alphacetylmethadol (levo-alpha-acetylmethadol, levomethadyl  
53 acetate, or LAAM);

54 ( \* \* \*8) Alphameprodine;

55 ( \* \* \*9) Alphamethadol;

56 ( \* \* \*10) Alpha-Methylfentanyl  
57 (N-[1-alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide;  
58 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine);

59 ( \* \* \*11) Alpha-Methylthiofentanyl

60 (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide  
61 );



62 ( \* \* \*12) Benzethidine;

63 ( \* \* \*13) Betacetylmethadol;

64 ( \* \* \*14) Beta-Hydroxyfentanyl  
65 (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);

66 ( \* \* \*15) Beta-Hydroxy-3-methylfentanyl  
67 (N-[1-(2-hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-phenylpr  
68 opionamide);

69 (16) Beta-Hydroxythiofentanyl  
70 (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpr  
71 opionamide);

72 ( \* \* \*17) Betameprodine;

73 ( \* \* \*18) Betamethadol;

74 (19) Beta-Methyl fentanyl  
75 (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide), also  
76 known as  $\beta$ -methyl fentanyl;

77 (20) Beta'-Phenyl fentanyl  
78 (N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide), also  
79 known as  $\beta'$ -phenyl fentanyl or 3-phenylpropanoyl fentanyl;

80 ( \* \* \*21) Betaprodine;

81 ( \* \* \*22) Butyrl fentanyl  
82 (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);

83 ( \* \* \*23) Clonitazene;

84 (24) Crotonyl fentanyl  
85 ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide);



86 (25) Cyclopentyl fentanyl  
87 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);

88 (26) Cyclopropyl fentanyl  
89 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);

90 ( \* \* \*27) Dextromoramide;

91 ( \* \* \*28) Diampromide;

92 ( \* \* \*29) Diethylthiambutene;

93 ( \* \* \*30) Difenoxyin;

94 ( \* \* \*31) Dimenoxadol;

95 ( \* \* \*32) Dimepheptanol;

96 ( \* \* \*33) Dimethylthiambutene;

97 ( \* \* \*34) Dioxaphetyl butyrate;

98 ( \* \* \*35) Dipipanone;

99 ( \* \* \*36) Ethylmethylthiambutene;

100 ( \* \* \*37) Etonitazene;

101 ( \* \* \*38) Etoxeridine;

102 (39) Fentanyl carbamate  
103 (ethyl(1-phenethylpiperidin-4-yl)(phenyl)carbamate);

104 ( \* \* \*40) Fentanyl-related substances, meaning any  
105 substance not otherwise listed under another schedule and for  
106 which no exemption or approval is in effect under Section 505 of  
107 the Federal Food, Drug, and Cosmetic Act [21 USC 355] that is  
108 structurally related to fentanyl by one or more of the following  
109 modifications:



110 (A) Replacement of the phenyl portion of the  
111 phenethyl group by any monocycle, whether or not further  
112 substituted in or on the monocycle;

113 (B) Substitution in or on the phenethyl group with  
114 alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl, amino or nitro  
115 groups;

116 (C) Substitution in or on the piperidine ring with  
117 alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl,  
118 amino or nitro groups;

119 (D) Replacement of the aniline ring with any  
120 aromatic monocycle whether or not further substituted in or on the  
121 aromatic monocycle; and/or

122 (E) Replacement of the N-propionyl group by  
123 another acyl group.

124 \* \* \*

125 (41) 4-Fluoroisobutyryl fentanyl  
126 (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide),  
127 also known as para-fluoroisobutyryl fentanyl);

128 (42) 2'-Fluoro ortho-fluorofentanyl  
129 (N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)  
130 propionamide), also known as 2'-fluoro 2-fluorofentanyl;

131 (43) Furanyl fentanyl  
132 (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide);

133 ( \* \* \*44) Furethidine;

134 ( \* \* \*45) Hydroxypethidine;



135 (46) Isobutyryl fentanyl  
136 (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide);  
137 ( \* \* \*47) Isotonitazene (N,N-diethyl-2-(2-(4  
138 isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);  
139 ( \* \* \*48) Ketobemidone (including the optical and  
140 geometric isomers);  
141 ( \* \* \*49) Levomoramide;  
142 ( \* \* \*50) Levophenacylmorphane;  
143 (51) Methoxyacetyl fentanyl  
144 (2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);  
145 (52) 4'-Methyl acetyl fentanyl  
146 (N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide);  
147 ( \* \* \*53) 3-Methylfentanyl  
148 (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);  
149 ( \* \* \*54) 3-Methylthiofentanyl (N-[3-methyl-1-  
150 (2-thienylethyl)-4-piperidinyl]-N-phenylpropanamide);  
151 ( \* \* \*55) Morpheridine;  
152 ( \* \* \*56) MPPP  
153 (1-methyl-4-phenyl-4-propionoxypiperidine);  
154 ( \* \* \*57) \* \* \* MT-45  
155 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);  
156 ( \* \* \*58) Noracymethadol;  
157 ( \* \* \*59) Norlevorphanol;  
158 ( \* \* \*60) Normethadone;  
159 ( \* \* \*61) Norpipanone;



160           (62) Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-  
161 (1-phenethylpiperidin-4-yl)acetamide);  
162           (63) Ortho-Fluoroacryl fentanyl  
163 (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide);  
164           (64) Ortho-Fluorobutyryl fentanyl  
165 (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide), also  
166 known as 2-fluorobutyryl fentanyl;  
167           (65) Ortho-Fluorofentanyl  
168 (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide),  
169 also known as 2-fluorofentanyl;  
170           (66) Ortho-Fluoroisobutyryl fentanyl  
171 (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);  
172           (67) Ortho-Methyl acetylfentanyl  
173 (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide), also  
174 known as 2-methyl acetylfentanyl;  
175           (68) Ortho-Methyl methoxyacetyl fentanyl  
176 (2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)  
177 acetamide), also known as 2-methyl methoxyacetyl fentanyl;  
178           (69) Para-Chloroisobutyryl fentanyl  
179 (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);  
180           (70) Para-Fluorobutyryl fentanyl  
181 (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);  
182           ( \* \* \*71) Para-Fluorofentanyl (N-(4-fluorophenyl)  
183 -N-[1-(2-phenylethyl)-4-piperidinyl]propanamide);  
184           (72) Para-Fluoro furanyl fentanyl N-(4-fluorophenyl)-N-



185 (1-phenethylpiperidin-4-yl) furan-2-carboxamide);  
186 (73) Para-Methoxybutyryl fentanyl  
187 (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);  
188 (74) Para-Methylfentanyl  
189 (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide),  
190 also known as 4-methylfentanyl);  
191 ( \* \* \*75) PEPAP  
192 (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);  
193 ( \* \* \*76) Phenadoxone;  
194 ( \* \* \*77) Phenampromide;  
195 ( \* \* \*78) Phenomorphan;  
196 ( \* \* \*79) Phenoperidine;  
197 (80) Phenyl fentanyl  
198 (N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide), also known as  
199 benzoyl fentanyl;  
200 ( \* \* \*81) Piritramide;  
201 ( \* \* \*82) Proheptazine;  
202 ( \* \* \*83) Properidine;  
203 ( \* \* \*84) Propiram;  
204 ( \* \* \*85) Racemoramide;  
205 (86) Tetrahydrofuran-2-yl fentanyl  
206 (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-  
207 carboxamide);  
208 ( \* \* \*87) Thiofentanyl  
209 (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]propanamide);





210                   (88) Thiofuranyl fentanyl  
211 (N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide),  
212 also known as 2-thiofuranyl fentanyl or thiophene fentanyl;

213                   ( \* \* \*89) Tilidine;

214                   ( \* \* \*90) Trimeperidine;

215                   ( \* \* \*91) U-47700, (3,4-dichloro-N-  
216 [2-(dimethylamino)cyclohexyl]-N-methylbenzamide) \* \* \*;

217                   (92) Valeryl fentanyl  
218 (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide).

219           (c) **Opium derivatives.** Unless specifically excepted or  
220 unless listed in another schedule, any of the following opium  
221 derivatives, their salts, isomers and salts of isomers, whenever  
222 the existence of these salts, isomers and salts of isomers is  
223 possible within the specific chemical designation:

224                   (1) Acetorphine;

225                   (2) Acetyldihydrocodeine;

226                   (3) Benzylmorphine;

227                   (4) Codeine methylbromide;

228                   (5) Codeine-N-Oxide;

229                   (6) Cyprenorphine;

230                   (7) Desomorphine;

231                   (8) Dihydromorphine;

232                   (9) Drotebanol;

233                   (10) Etorphine (except hydrochloride salt);

234                   (11) Heroin;



- 235 (12) Hydromorphinol;
- 236 (13) Methyldesorphine;
- 237 (14) Methyldihydromorphine;
- 238 (15) Monoacetylmorphine;
- 239 (16) Morphine methylbromide;
- 240 (17) Morphine methylsulfonate;
- 241 (18) Morphine-N-Oxide;
- 242 (19) Myrophine;
- 243 (20) Nicocodeine;
- 244 (21) Nicomorphine;
- 245 (22) Normorphine;
- 246 (23) Pholcodine;
- 247 (24) Thebacon.

248 (d) **Hallucinogenic substances.** Unless specifically excepted  
249 or unless listed in another schedule, any material, compound,  
250 mixture or preparation which contains any quantity of the  
251 following substances, their salts, isomers (whether optical,  
252 positional, or geometric) and salts of isomers, whenever the  
253 existence of these salts, isomers and salts of isomers is possible  
254 within the specific chemical designation:

- 255 (1) Alpha-ethyltryptamine;
- 256 (2) 4-bromo-2,5-dimethoxy-amphetamine;
- 257 (3) 4-bromo-2,5-dimethoxyphenethylamine;
- 258 (4) 2,5-dimethoxyamphetamine;
- 259 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET);



- 260 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine  
261 (2C-T-7);
- 262 (7) 4-methoxyamphetamine;
- 263 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 264 (9) 4-methyl-2,5-dimethoxy-amphetamine;
- 265 (10) 3,4-methylenedioxy amphetamine;
- 266 (11) 3,4-methylenedioxymethamphetamine (MDMA);
- 267 (12) 3,4-methylenedioxy-N-ethylamphetamine (also known  
268 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl  
269 MDA, MDE, MDEA);
- 270 (13) N-hydroxy-3,4-methylenedioxyamphetamine (also  
271 known as N-hydroxy MDA, N-OHMDA, and  
272 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine);
- 273 (14) 3,4,5-trimethoxy amphetamine;
- 274 (15) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 275 (16) Alpha-methyltryptamine (also known as AMT);
- 276 (17) Bufotenine;
- 277 (18) Diethyltryptamine;
- 278 (19) Dimethyltryptamine;
- 279 (20) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
- 280 (21) Ibogaine;
- 281 (22) Lysergic acid diethylamide (LSD);
- 282 (23) (A) Marijuana (Hemp as defined and regulated  
283 under Sections 69-25-201 through 69-25-221 and Cannabidiol  
284 contained in a legend drug product approved by the Federal Food



285 and Drug Administration or obtained under Section 41-29-136 are  
286 exempt under Schedule I);

287 (B) Hashish;

288 (24) Mescaline;

289 (25) Parahexyl;

290 (26) Peyote;

291 (27) N-ethyl-3-piperidyl benzilate;

292 (28) N-methyl-3-piperidyl benzilate;

293 (29) Psilocybin;

294 (30) Psilocyn;

295 (31) Tetrahydrocannabinols, meaning

296 tetrahydrocannabinols contained in a plant of the genus Cannabis  
297 (cannabis plant), as well as the synthetic equivalents of the  
298 substances contained in the cannabis plant, or in the resinous  
299 extractives of such plant, and/or synthetic substances,

300 derivatives, and their isomers with similar chemical structure and  
301 pharmacological activity to those substances contained in the  
302 plant such as the following:

303 (A) 1 cis or trans tetrahydrocannabinol;

304 (B) 6 cis or trans tetrahydrocannabinol;

305 (C) 3,4 cis or trans tetrahydrocannabinol.

306 (Since nomenclature of these substances is not  
307 internationally standardized, compounds of these structures,  
308 regardless of atomic positions, are covered.)



309 ("Tetrahydrocannabinols" excludes dronabinol and nabilone.)  
310 For purposes of this paragraph, tetrahydrocannabinols do not  
311 include hemp or hemp products regulated under Sections 69-25-201  
312 through 69-25-221.

313 However, the following products are exempted from control:

314 (i) THC-containing industrial products made  
315 from cannabis stalks (e.g., paper, rope and clothing);

316 (ii) Processed cannabis plant materials used  
317 for industrial purposes, such as fiber retted from cannabis stalks  
318 for use in manufacturing textiles or rope;

319 (iii) Animal feed mixtures that contain  
320 sterilized cannabis seeds and other ingredients (not derived from  
321 the cannabis plant) in a formula designed, marketed and  
322 distributed for nonhuman consumption;

323 (iv) Personal care products that contain oil  
324 from sterilized cannabis seeds, such as shampoos, soaps, and body  
325 lotions (if the products do not cause THC to enter the human  
326 body);

327 (v) Hemp as regulated under Sections  
328 69-25-201 through 69-25-221; and

329 (vi) Any product derived from the hemp plant  
330 designed for human ingestion and/or consumption that is approved  
331 by the United States Food and Drug Administration;

332 (32) Phencyclidine;

333 (33) Ethylamine analog of phencyclidine (PCE);



334 (34) Pyrrolidine analog of phencyclidine (PHP, PCPy);  
335 (35) Thiophene analog of phencyclidine;  
336 (36) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine (TCPy);  
337 (37) 4-methylmethcathinone (mephedrone);  
338 (38) 3,4-methylenedioxypropylvalerone (MDPV);  
339 (39) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E);  
340 (40) 2-(2,5-dimethoxy-4-methylphenyl)ethanamine (2C-D);  
341 (41) 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);  
342 (42) 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);  
343 or 2,5-dimethoxy-4-iodophenethylamine;  
344 (43) 2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine  
345 (2C-T-2);  
346 (44)  
347 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);  
348 (45) 2-(2,5-dimethoxyphenyl)ethanamine (2C-H);  
349 (46) 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N);  
350 (47) 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine  
351 (2C-P);  
352 (48) 3,4-methylenedioxy-N-methylcathinone (methylone);  
353 (49)  
354 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine  
355 (25B-NBOMe; 2C-B-NBOMe; 25B; Cimi-36);  
356 (50)  
357 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine  
358 (25C-NBOMe; 2C-C-NBOMe; 25C; Cimi-82);



359 (51)  
360 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine or  
361 N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I;  
362 Cimbi-5);

363 (52) 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,  
364 4-benzodiazepin-2-one (also known as Phenazepam);

365 (53) 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,  
366 11,12-tetraazatricyclo[8.3.0.0]trideca-2(6),4,7,10,12-pentaene  
367 (also known as Etizolam);

368 (54) *Salvia divinorum*;

369 (55) Synthetic cannabinoids. Unless specifically  
370 excepted or unless listed in another schedule, any material,  
371 compound, mixture, or preparation which contains any quantity of a  
372 synthetic cannabinoid found in any of the following chemical  
373 groups, whether or not substituted to any extent, or any of those  
374 groups which contain any synthetic cannabinoid salts, isomers, or  
375 salts of isomers, whenever the existence of such salts, isomers,  
376 or salts of isomers is possible within the specific chemical  
377 designation, including all synthetic cannabinoid chemical  
378 analogues in such groups:

379 (A) (6aR,10aR)-9-(hydroxymethyl)-6,  
380 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]  
381 chromen-1-ol (also known as HU-210 or  
382 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol);



383 (B) Naphthoylindoles and naphthylmethylindoles,  
384 being any compound structurally derived from 3-(1-naphthoyl)indole  
385 or 1H-indol-3-yl-(1-naphthyl)methane, whether or not substituted  
386 in the indole ring to any extent, or in the naphthyl ring to any  
387 extent;

388 (C) Naphthoylpyrroles, being any compound  
389 structurally derived from 3-(1-naphthoyl)pyrrole, whether or not  
390 substituted in the pyrrole ring to any extent, or in the naphthyl  
391 ring to any extent;

392 (D) Naphthylmethylindenes, being any compound  
393 structurally derived from 1-(1-naphthylmethyl)indene, whether or  
394 not substituted in the indene ring to any extent or in the  
395 naphthyl ring to any extent;

396 (E) Phenylacetylindoles, being any compound  
397 structurally derived from 3-phenylacetylindole, whether or not  
398 substituted in the indole ring to any extent or in the phenyl ring  
399 to any extent;

400 (F) Cyclohexylphenols, being any compound  
401 structurally derived from 2-(3-hydroxycyclohexyl)phenol, whether  
402 or not substituted in the cyclohexyl ring to any extent or in the  
403 phenolic ring to any extent;

404 (G) Benzoylindoles, whether or not substituted in  
405 the indole ring to any extent or in the phenyl ring to any extent;





406 (H) Adamantoylindoles, whether or not substituted  
407 in the indole ring to any extent or in the adamantoyl ring system  
408 to any extent;

409 (I) Tetrahydro derivatives of cannabinal and  
410 3-alkyl homologues of cannabinal or of its tetrahydro derivatives,  
411 except where contained in cannabis or cannabis resin;

412 (J) 3-Cyclopropylmethanone indole or  
413 3-Cyclobutylmethanone indole or 3-Cyclopentylmethanone indole by  
414 substitution at the nitrogen atom of the indole ring, whether or  
415 not further substituted in the indole ring to any extent, whether  
416 or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl  
417 rings to any extent;

418 (K) Quinoliny ester indoles, being any compound  
419 structurally derived from 1H-indole-3carboxylic acid-8-quinoliny  
420 ester, whether or not substituted in the indole ring to any extent  
421 or the quinolone ring to any extent;

422 (L) 3-carboxamide-1H-indazoles, whether or not  
423 substituted in the indazole ring to any extent and substituted to  
424 any degree on the carboxamide nitrogen and  
425 3-carboxamide-1H-indoles, whether or not substituted in the indole  
426 ring to any extent and substituted to any degree on the  
427 carboxamide nitrogen;

428 (M) Cycloalkanemethanone Indoles, whether or not  
429 substituted at the nitrogen atom on the indole ring, whether or



430 not further substituted in the indole ring to any extent, whether  
431 or not substituted on the cycloalkane ring to any extent \* \* \*;

432 (56) Naphthalen-1-yl  
433 1-(5-fluoropentyl)-1H-indole-3-carboxylate, also known as NM2201  
434 or CBL2201;

435 (57) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-  
436 pyrrolo[2,3-b]pyridine-3-carboxamide, also known as  
437 5F-CUMYL-P7AICA;

438 (58) 1-(4-methoxyphenyl)-N-methylpropan-2-amine, also  
439 known as para-methoxymethamphetamine or PMMA.

440 (e) **Depressants.** Unless specifically excepted or unless  
441 listed in another schedule, any material, compound, mixture, or  
442 preparation which contains any quantity of the following  
443 substances having a depressant effect on the central nervous  
444 system, including their salts, isomers, and salts of isomers,  
445 whenever the existence of such salts, isomers, and salts of  
446 isomers is possible within the specific chemical designation:

447 (1) Clonazepam,  
448 6-(2-chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]  
449 benzodiazepine;

450 (2) Flualprazolam,  
451 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4  
452 ]benzodiazepine;

453 (3) Flubromazepam,  
454 7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one;



455 (4) Flubromazolam,  
456 8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]  
457 benzodiazepin;

458 (5) Gamma-hydroxybutyric acid (other names include:  
459 GHB, gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic  
460 acid; sodium oxybate; sodium oxybutyrate);

461 (6) Mecloqualone;

462 (7) Methaqualone.

463 (f) **Stimulants.** Any material, compound, mixture or  
464 preparation which contains any quantity of the following central  
465 nervous system stimulants including optical salts, isomers and  
466 salts of isomers unless specifically excepted or unless listed in  
467 another schedule:

468 (1) Aminorex;

469 (2) N-benzylpiperazine (also known as BZP and  
470 1-benzylpiperazine);

471 (3) Cathinone;

472 (4) Fenethylamine;

473 (5) Methcathinone;

474 (6) 4-methylaminorex (also known as  
475 2-amino-4-methyl-5-phenyl-2-oxazoline);

476 (7) N-ethylamphetamine;

477 (8) Any material, compound, mixture or preparation  
478 which contains any quantity of N,N-dimethylamphetamine. (Other



479 names include: N,N,-alpha-trimethyl-benzeneethanamine and  
480 N,N-alpha-trimethylphenethylamine);

481 (9) **Synthetic cathinones.** (A) Unless listed in  
482 another schedule, any compound other than bupropion that is  
483 structurally derived from 2-Amino-1-phenyl-1-propanone by  
484 modification in any of the following ways:

485 (i) By substitution in the phenyl ring to any  
486 extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide  
487 substituents, whether or not further substituted in the phenyl  
488 ring by one or more other univalent substituents;

489 (ii) By substitution at the 3-position with  
490 an alkyl substituent;

491 (iii) By substitution at the nitrogen atom  
492 with alkyl or dialkyl groups, or by inclusion of the nitrogen atom  
493 in a cyclic structure.

494 (B) The compounds covered in this paragraph (9)  
495 include, but are not limited to, any material, compound, mixture  
496 or preparation which contains any quantity of a synthetic  
497 cathinone found in any of the following compounds, whether or not  
498 substituted to any extent, or any of these compounds which contain  
499 any synthetic cathinone, or salts, isomers, or salts of isomers,  
500 whenever the existence of such salts, isomers or salts of isomers  
501 is possible, unless specifically excepted or listed in another  
502 schedule:

503 (i) 4-methyl-N-ethylcathinone ("4-MEC");



504 (ii) 4-methyl-alpha-pyrrolidinopropiophenone  
505 ("4-MePPP");  
506 (iii) Alpha-pyrrolidinopentiophenone  
507 ("α-PVP");  
508 (iv)  
509 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one ("butylone");  
510 (v) 2-(methylamino)-1-phenylpentan-1-one  
511 ("pentedrone");  
512 (vi)  
513 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one  
514 ("pentylone");  
515 (vii) 4-fluoro-N-methylcathinone ("4-FMC");  
516 (viii) 3-fluoro-N-methylcathinone ("3-FMC");  
517 (ix)  
518 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one ("naphyrone");  
519 (x) Alpha-pyrrolidinobutiophenone ("α-PBP");  
520 and  
521 (xi)  
522 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one  
523 (N-ethylpentylone, ephylone).

524 **SECTION 2.** Section 41-29-115, Mississippi Code of 1972, is  
525 amended as follows:

526 41-29-115. (a) The controlled substances listed in this  
527 section, by whatever official name, common or usual name, chemical  
528 name, or brand name designated, are included in Schedule II.



529 **SCHEDULE II**

530 (b) **Substances, vegetable origin or chemical synthesis.**

531 Unless specifically excepted or unless listed in other schedules,  
532 any of the following substances, whether produced directly or  
533 indirectly by extraction from substances of vegetable origin, or  
534 independently by means of chemical synthesis, or by combination of  
535 extraction and chemical synthesis:

536 (1) Opium and opiate, and any salt, compound,  
537 derivative, or preparation of opium or opiate, excluding  
538 apomorphine, thebaine-derived butorphanol, dextrophan,  
539 nalbuphine, naldemedine, nalmeferone, naloxegol, naloxone and  
540 naltrexone, but including the following:

- 541 (i) Codeine;
- 542 (ii) Dihydroetorphine;
- 543 (iii) Ethylmorphine;
- 544 (iv) Etorphine hydrochloride;
- 545 (v) Granulated opium;
- 546 (vi) Hydrocodone, whether alone or in combination  
547 with any material, compound, mixture or preparation;
- 548 (vii) Hydromorphone;
- 549 (viii) Metopon;
- 550 (ix) Morphine;
- 551 (x) Opium extracts;
- 552 (xi) Opium fluid extracts;
- 553 (xii) Oripavine;



554 (xiii) Oxycodone;  
555 (xiv) Oxymorphone;  
556 (xv) Powdered opium;  
557 (xvi) Raw opium;  
558 (xvii) Thebaine;  
559 (xviii) Tincture of opium;  
560 (2) Any salt, compound, isomer, derivative, or  
561 preparation thereof which is chemically equivalent or identical  
562 with any of the substances referred to in paragraph (1), but not  
563 including the isoquinoline alkaloids of opium;  
564 (3) Opium poppy and poppy straw;  
565 (4) Coca leaves and any salt, compound, derivative, or  
566 preparation of cocaine or coca leaves, including cocaine and  
567 ecgonine and any salt, compound, derivative, isomer, or  
568 preparation thereof which is chemically equivalent or identical  
569 with any of these substances, but not including:  
570 (i) Decocainized coca leaves or extraction of coca  
571 leaves, which extractions do not contain cocaine or ecgonine; or  
572 (ii) Ioflupane;  
573 (5) Concentrate of poppy straw (the crude extract of  
574 poppy straw in either liquid, solid or powder form which contains  
575 the phenanthrene alkaloids of the opium poppy).  
576 (c) **Opiates.** Any of the following opiates, including their  
577 isomers, esters, ethers, salts, and salts of isomers, whenever the  
578 existence of these isomers, esters, ethers and salts is possible



579 within the specified chemical designation, dextrorphan and  
580 levopropoxyphene excepted:

- 581 (1) Alfentanil;
- 582 (2) Alphaprodine;
- 583 (3) Anileridine;
- 584 (4) Bezitramide;
- 585 (5) Bulk dextropropoxyphene (nondosage forms);
- 586 (6) Carfentanil;
- 587 (7) Dihydrocodeine;
- 588 (8) Diphenoxylate;
- 589 (9) Fentanyl;
- 590 (10) Isomethadone;
- 591 (11) Levo-alpha-acetylmethadol  
592 (levo-alpha-acetylmethadol, levomethadyl acetate, LAAM);
- 593 (12) Levomethorphan;
- 594 (13) Levorphanol;
- 595 (14) Metazocine;
- 596 (15) Methadone;
- 597 (16) Methadone-intermediate,  
598 4-cyano-2-dimethylamino-4,4-diphenyl butane;
- 599 (17) Moramide-intermediate,  
600 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid;
- 601 (18) Oliceridine  
602 (N-[(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-  
603 oxaspiro[4.5]decan-9-yl]ethyl})amine);





604 ( \* \* \*19) Pethidine (meperidine);  
605 ( \* \* \*20) Pethidine-Intermediate-A,  
606 4-cyano-1-methyl-4-phenylpiperidine;  
607 ( \* \* \*21) Pethidine-Intermediate-B,  
608 ethyl-4-phenylpiperidine-4-carboxylate;  
609 ( \* \* \*22) Pethidine-Intermediate-C,  
610 1-methyl-4-phenylpiperidine-4-carboxylic acid;  
611 ( \* \* \*23) Phenazocine;  
612 ( \* \* \*24) Piminodine;  
613 ( \* \* \*25) Racemethorphan;  
614 ( \* \* \*26) Racemorphan;  
615 ( \* \* \*27) Remifentanil;  
616 ( \* \* \*28) Sufentanil;  
617 ( \* \* \*29) Tapentadol;  
618 ( \* \* \*30) Thiafentanil, methyl  
619 4-(2-methoxy-N-phenylacetamido)-1-(2-(thiophen-2-yl)ethyl)  
620 piperidine-4-carboxylate).

621 (d) **Stimulants.** Any material, compound, mixture, or  
622 preparation which contains any quantity of the following  
623 substances:

- 624 (1) Amphetamine, its salts, optical isomers, and salts  
625 of its optical isomers;  
626 (2) Phenmetrazine and its salts;



627 (3) Any substance which contains any quantity of  
628 methamphetamine, including its salts, isomers, and salts of  
629 isomers;

630 (4) Methylphenidate and its salts;

631 (5) Lisdexamfetamine, its salts, isomers and salts of  
632 isomers.

633 (e) **Depressants.** Unless specifically exempted or unless  
634 listed in another schedule, any material, compound, mixture, or  
635 preparation which contains any quantity of the following  
636 substances:

637 (1) Amobarbital;

638 (2) Secobarbital;

639 (3) Pentobarbital;

640 (4) Glutethimide.

641 (f) **Hallucinogenic substances.**

642 (1) Dronabinol oral solution  
643 [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)];

644 (2) Nabilone [other names include:  
645 (+/-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-  
646 hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one].

647 (g) **Immediate precursors.** Unless specifically excepted or  
648 unless listed in another schedule, any material, compound,  
649 mixture, or preparation which contains any quantity of the  
650 following substances:



651 (1) Amphetamine and methamphetamine immediate  
652 precursor: Phenylacetone (other names include:  
653 phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl  
654 ketone);

655 (2) Phencyclidine immediate precursors:

656 (i) 1-phenylcyclohexylamine;

657 (ii) 1-piperidinocyclohexanecarbonitrile (PCC);

658 (3) Fentanyl immediate precursor:

659 4-anilino-N-phenethyl-4-piperidine (ANPP).

660 (h) Any material, compound, mixture or preparation which  
661 contains any quantity of a Schedule II controlled substance and is  
662 listed as an exempt substance in 21 CFR, Section 1308.24 or  
663 1308.32, shall be exempted from the provisions of the Uniform  
664 Controlled Substances Law.

665 **SECTION 3.** Section 41-29-119, Mississippi Code of 1972, is  
666 amended as follows:

667 41-29-119. (A) The controlled substances listed in this  
668 section are included in Schedule IV.

669 **SCHEDULE IV**

670 (a) **Narcotic drugs.** Unless specifically excepted or  
671 unless listed in another schedule, any material, compound, mixture  
672 or preparation which contains limited quantities of the following  
673 narcotic drugs, or any salts thereof:



674 (1) Not more than one (1) milligram of difenoxin  
675 and not less than twenty-five (25) micrograms of atropine sulfate  
676 per dosage unit;

677 (2) Dextropropoxyphene, including its salts  
678 (Darvon, Darvon-N; also found in Darvon compound and Darvocet-N,  
679 etc.);

680 (3)  
681 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its  
682 salts, optical and geometric isomers and salts of these isomers  
683 (including tramadol).

684 (b) **Depressants.** Any material, compound, mixture or  
685 preparation which contains any quantity of the following  
686 substances:

687 (1) Alfaxalone;

688 (2) Alprazolam;

689 (3) Barbitol;

690 (4) Brexanolone;

691 (5) Bromazepam;

692 (6) Camazepam;

693 (7) Carisoprodol;

694 (8) Chloral betaine;

695 (9) Chloral hydrate;

696 (10) Chlordiazepoxide and its salts, but does not  
697 include chlordiazepoxide hydrochloride and clidinium bromide or  
698 chlordiazepoxide and esterified estrogens;



- 699 (11) Clobazam;
- 700 (12) Clonazepam;
- 701 (13) Clorazepate;
- 702 (14) Clotiazepam;
- 703 (15) Cloxazolam;
- 704 (16) Delorazepam;
- 705 (17) Diazepam;
- 706 (18) Dichloralphenazone;
- 707 (19) Estazolam;
- 708 (20) Ethchlorvynol;
- 709 (21) Ethinamate;
- 710 (22) Ethyl loflazepate;
- 711 (23) Fludiazepam;
- 712 (24) Flunitrazepam;
- 713 (25) Flurazepam;
- 714 (26) Fospropofol;
- 715 (27) Halazepam;
- 716 (28) Haloxazolam;
- 717 (29) Ketazolam;
- 718 (30) Lemborexant;
- 719 ( \* \* \*31) Loprazolam;
- 720 ( \* \* \*32) Lorazepam;
- 721 ( \* \* \*33) Lormetazepam;
- 722 ( \* \* \*34) Mebutamate;
- 723 ( \* \* \*35) Medazepam;



724 ( \* \* \*36) Meproamate;  
725 ( \* \* \*37) Methohexital;  
726 ( \* \* \*38) Methylphenobarbital;  
727 ( \* \* \*39) Midazolam;  
728 ( \* \* \*40) Nimetazepam;  
729 ( \* \* \*41) Nitrazepam;  
730 ( \* \* \*42) Nordiazepam;  
731 ( \* \* \*43) Oxazepam;  
732 ( \* \* \*44) Oxazolam;  
733 ( \* \* \*45) Paraldehyde;  
734 ( \* \* \*46) Petrichloral;  
735 ( \* \* \*47) Phenobarbital;  
736 ( \* \* \*48) Pinazepam;  
737 ( \* \* \*49) Prazepam;  
738 ( \* \* \*50) Quazepam;  
739 (51) Remimazolam;  
740 ( \* \* \*52) Suvorexant;  
741 ( \* \* \*53) Temazepam;  
742 ( \* \* \*54) Tetrazepam;  
743 ( \* \* \*55) Triazolam;  
744 ( \* \* \*56) Zaleplon;  
745 ( \* \* \*57) Zolpidem;  
746 ( \* \* \*58) Zopiclone.  
747 (c) **Fenfluramine.**



748 (d) **Lorcaserin.** Any material, compound, mixture, or  
749 preparation which contains any quantity of Lorcaserin, including  
750 its salts, isomers, and salts of such isomers, whenever the  
751 existence of such salts, isomers, and salts of isomers is  
752 possible.

753 (e) **Stimulants.** Any material, compound, mixture or  
754 preparation which contains any quantity of the following  
755 substances:

- 756 (1) Cathine ((+/-) Norpseudoephedrine);
- 757 (2) Diethylpropion;
- 758 (3) Fencamfamin;
- 759 (4) Fenproporex;
- 760 (5) Mazindol;
- 761 (6) Mefenorex;
- 762 (7) Modafinil;
- 763 (8) Pemoline (including any organometallic  
764 complexes and chelates thereof);
- 765 (9) Phentermine;
- 766 (10) Pipradrol;
- 767 (11) Sibutramine;
- 768 (12) Solriamfetol;
- 769 (13) SPA ((-)-1-dimethylamino-1,2-diphenylethane).

770 (f) **Other substances.**

- 771 (1) Pentazocine;
- 772 (2) Butorphanol (including its optical isomers);



773 (3) Eluxadoline  
774 (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopr  
775 opyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-meth  
776 oxybenzoic acid); (including its optical isomers) and its salts,  
777 isomers, and salts of isomers.

778 (B) Any material, compound, mixture or preparation which  
779 contains any quantity of a Schedule IV controlled substance and is  
780 listed as an exempt substance in 21 CFR, Section 1308.22, 1308.24,  
781 1308.26, 1308.32 or 1308.34, shall be exempted from the provisions  
782 of the Uniform Controlled Substances Law.

783 **SECTION 4.** Section 41-29-121, Mississippi Code of 1972, is  
784 amended as follows:

785 41-29-121.

786 **SCHEDULE V**

787 (a) Schedule V consists of the drugs and other substances,  
788 by whatever official name, common or usual name, chemical name, or  
789 brand name designated, listed in this section.

790 (b) Narcotic drugs. [Reserved]

791 (c) **Narcotic drugs containing nonnarcotic active medicinal**  
792 **ingredients.** Any compound, mixture or preparation containing any  
793 of the following narcotic drugs, or their salts calculated as the  
794 free anhydrous base or alkaloid, in limited quantities as set  
795 forth below, which also contains one or more nonnarcotic active  
796 medicinal ingredients in sufficient proportion to confer upon the





797 compound, mixture or preparation valuable medicinal qualities  
798 other than those possessed by the narcotic drug alone:

799 (1) Not more than two hundred (200) milligrams of  
800 codeine, or any of its salts, per one hundred (100) milliliters or  
801 per one hundred (100) grams;

802 (2) Not more than one hundred (100) milligrams of  
803 dihydrocodeine, or any of its salts, per one hundred (100)  
804 milliliters or per one hundred (100) grams;

805 (3) Not more than one hundred (100) milligrams of  
806 ethylmorphine, or any of its salts, per one hundred (100)  
807 milliliters or per one hundred (100) grams;

808 (4) Not more than two and five-tenths (2.5) milligrams  
809 of diphenoxylate and not less than twenty-five (25) micrograms of  
810 atropine sulphate per dosage unit;

811 (5) Not more than one hundred (100) milligrams of opium  
812 per one hundred (100) milliliters or per one hundred (100) grams;

813 (6) Not more than five-tenths (0.5) milligram of  
814 difenoxin and not less than twenty-five (25) micrograms of  
815 atropine sulfate per dosage unit.

816 (d) **Stimulants.** Unless specifically excepted or listed in  
817 another schedule, any material, compound, mixture or preparation  
818 which contains any quantity of the following substance, including  
819 its salts, isomers and salts of isomers: Pyrovalerone.

820 (e) **Depressants.** Unless specifically exempted or excluded  
821 or unless listed in another schedule, any material, compound,



822 mixture or preparation which contains any quantity of the  
823 following substances having a depressant effect on the central  
824 nervous system, including their salts, isomers and salts of  
825 isomers:

826 (1) Brivaracetam  
827 ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also  
828 referred to as BRV; UCB-34714; Briviact);

829 (2) Cenobamate  
830 [(1R)-1-(2-chlorophenyl)-2-tetrazol-2-yl]ethyl] carbamate;  
831 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate  
832 (ester), (alphaR)-; carbamic acid (R)-(+)-1-(2-chlorophenyl)  
833 -2-(2H-tetrazol-2-yl)ethyl ester);

834 ( \* \* \*3) Ezogabine [N-[2-amino-4-(4-  
835 fluorobenzylamino)-phenyl]-carbamic acid ethyl ester];

836 ( \* \* \*4) Lacosamide  
837 [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide];

838 (5) Lasmiditan [2,4,6-trifluoro-N-(6-  
839 (1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide];

840 ( \* \* \*6) Pregabalin  
841 [(S)-3-(aminomethyl)-5-methylhexanoic acid].

842 (f) Any material, compound, mixture or preparation which  
843 contains any quantity of a Schedule V controlled substance and is  
844 listed as an exempt substance in 21 CFR, Section 1308.22, 1308.24,  
845 1308.26, 1308.32 or 1308.34, shall be exempted from the provisions  
846 of the Uniform Controlled Substances Law.



847           **SECTION 5.** Section 41-29-137, Mississippi Code of 1972, is  
848 amended as follows:

849           41-29-137. (a) (1) Except when dispensed directly by a  
850 practitioner, other than a pharmacy, to an ultimate user, no  
851 controlled substance in Schedule II, as set out in Section  
852 41-29-115, may be dispensed without the written valid prescription  
853 of a practitioner. A practitioner shall keep a record of all  
854 controlled substances in Schedule I, II and III administered,  
855 dispensed or professionally used by him otherwise than by  
856 prescription.

857           (2) In emergency situations, as defined by rule of the  
858 State Board of Pharmacy, Schedule II drugs may be dispensed upon  
859 the oral valid prescription of a practitioner, reduced promptly to  
860 writing and filed by the pharmacy. Prescriptions shall be  
861 retained in conformity with the requirements of Section 41-29-133.  
862 No prescription for a Schedule II substance may be refilled unless  
863 renewed by prescription issued by a licensed medical doctor.

864           (b) Except when dispensed directly by a practitioner, other  
865 than a pharmacy, to an ultimate user, a controlled substance  
866 included in Schedule III or IV, as set out in Sections 41-29-117  
867 and 41-29-119, shall not be dispensed without a written or oral  
868 valid prescription of a practitioner. The prescription shall not  
869 be filled or refilled more than six (6) months after the date  
870 thereof or be refilled more than five (5) times, unless renewed by  
871 the practitioner.



872 (c) A controlled substance included in Schedule V, as set  
873 out in Section 41-29-121, shall not be distributed or dispensed  
874 other than for a medical purpose.

875 (d) An optometrist certified to prescribe and use  
876 therapeutic pharmaceutical agents under Sections 73-19-153 through  
877 73-19-165 shall \* \* \* have the prescriptive authority granted in  
878 Section 73-19-157.

879 (e) Administration by injection of any pharmaceutical  
880 product authorized in this section is expressly prohibited except  
881 when dispensed directly by a practitioner other than a pharmacy.

882 (f) (1) For the purposes of this article, Title 73, Chapter  
883 21, and Title 73, Chapter 25, Mississippi Code of 1972, as it  
884 pertains to prescriptions for controlled substances, a "valid  
885 prescription" means a prescription that is issued for a legitimate  
886 medical purpose in the usual course of professional practice by:

887 (A) A practitioner who has conducted at least one  
888 (1) in-person medical evaluation of the patient, except as  
889 otherwise authorized by Section 41-29-137.1; or

890 (B) A covering practitioner.

891 (2) (A) "In-person medical evaluation" means a medical  
892 evaluation that is conducted with the patient in the physical  
893 presence of the practitioner, without regard to whether portions  
894 of the evaluation are conducted by other health professionals.

895 (B) "Covering practitioner" means a practitioner  
896 who conducts a medical evaluation other than an in-person medical



897 evaluation at the request of a practitioner who has conducted at  
898 least one (1) in-person medical evaluation of the patient or an  
899 evaluation of the patient through the practice of telemedicine  
900 within the previous twenty-four (24) months and who is temporarily  
901 unavailable to conduct the evaluation of the patient.

902 (3) A prescription for a controlled substance based  
903 solely on a consumer's completion of an online medical  
904 questionnaire is not a valid prescription.

905 (4) Nothing in this subsection (f) shall apply to:

906 (A) A prescription issued by a practitioner  
907 engaged in the practice of telemedicine as authorized under state  
908 or federal law; or

909 (B) The dispensing or selling of a controlled  
910 substance pursuant to practices as determined by the United States  
911 Attorney General by regulation.

912 **SECTION 6.** This act shall take effect and be in force from  
913 and after its passage.

**Further, amend by striking the title in its entirety and  
inserting in lieu thereof the following:**

1 AN ACT TO AMEND SECTION 41-29-113, MISSISSIPPI CODE OF 1972,  
2 TO INCLUDE 20 FENTANYL-RELATED SUBSTANCES, MT-45, NM2201,  
3 5F-CUMYL-P7AICA AND PMMA AS SCHEDULE I CONTROLLED SUBSTANCES  
4 BECAUSE THESE DRUGS HAVE NO LEGITIMATE MEDICAL USE AND HAVE A HIGH  
5 POTENCY WITH GREAT POTENTIAL TO CAUSE HARM; TO ALPHABETIZE CERTAIN  
6 SUBSTANCES TO CONFORM THE LIST OF SCHEDULE I OPIATES TO THE CODE  
7 OF FEDERAL REGULATIONS; TO AMEND SECTION 41-29-115, MISSISSIPPI  
8 CODE OF 1972, TO INCLUDE OLICERIDINE AS A SCHEDULE II CONTROLLED  
9 SUBSTANCE BECAUSE OLICERIDINE HAS A CURRENTLY ACCEPTED MEDICAL USE  
10 BUT HAS A HIGH POTENTIAL FOR ABUSE THAT MAY LEAD TO SEVERE



11 PSYCHOLOGICAL OR PHYSICAL DEPENDENCE; TO AMEND SECTION 41-29-119,  
12 MISSISSIPPI CODE OF 1972, TO INCLUDE LEMBOREXANT AND REMIMAZOLAM  
13 AS SCHEDULE IV CONTROLLED SUBSTANCES BECAUSE THESE DRUGS HAVE A  
14 CURRENTLY ACCEPTED MEDICAL USE AND A LOW POTENTIAL FOR ABUSE THAT  
15 MAY LEAD TO LIMITED PHYSICAL DEPENDENCE OR PSYCHOLOGICAL  
16 DEPENDENCE RELATIVE TO THE DRUGS OR OTHER SUBSTANCES IN SCHEDULE  
17 III; TO AMEND SECTION 41-29-121, MISSISSIPPI CODE OF 1972, TO  
18 INCLUDE CENOBAMATE AND LASMIDITAN AS SCHEDULE V CONTROLLED  
19 SUBSTANCES BECAUSE THESE DRUGS HAVE A CURRENTLY ACCEPTED MEDICAL  
20 USE AND A LOW POTENTIAL FOR ABUSE THAT MAY LEAD TO LIMITED  
21 PHYSICAL DEPENDENCE OR PSYCHOLOGICAL DEPENDENCE RELATIVE TO THE  
22 DRUGS OR OTHER SUBSTANCES IN SCHEDULE IV; TO AMEND SECTION  
23 41-29-137, MISSISSIPPI CODE OF 1972, TO CONFORM TO EXISTING LAW  
24 REGARDING THE PRESCRIPTIVE AUTHORITY OF OPTOMETRISTS; AND FOR  
25 RELATED PURPOSES.

